April 14, 2020—The American Heart Association (AHA), the American College of Cardiology (ACC), and the Heart Rhythm Society (HRS) jointly developed this new guidance to detail critical cardiovascular considerations in the use of hydroxychloroquine and azithromycin for the treatment of COVID-19. The statement also includes a table rating potential adverse cardiac events of medications repurposed for COVID-19 treatment, such as chloroquine and lopinavir/ritonavir (antimalarial and antiviral agents, respectively).
Recommended Resources:Â HRS COVID-19 Challenges & Solutions
Related Resources
Clinical Guidelines
2026 HRS/AHA/APHRS/EHRA/IDSA/LAHRS/PACES/STS Expert Consensus Statement Update on Cardiovascular Implantable Electronic Device Lead Management and Extraction
Provides updated guidance on CIED lead management and extraction, including indications, procedural safety, and team-based care.
April 23, 2026
Clinical Guidelines
2025 SCAI/HRS Clinical Practice Guidelines on Transcatheter Left Atrial Appendage Occlusion
Evidence-based guidance from SCAI and HRS on the use of transcatheter left atrial appendage occlusion for stroke prevention in atrial fibrillation, including patient selection, imaging,…
August 4, 2025
Clinical Guidelines
2024 HRS Expert Consensus Statement on Arrhythmias in the Athlete: Evaluation, Treatment, and Return to Play
Guidance on evaluating and managing arrhythmias in athletes, including risk stratification, treatment options, and return-to-play decision-making.
May 17, 2024